human tonsil-derived mesenchymal stem cell (CT303) / GC Biopharma - LARVOL DELTA

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: GC Cell Corporation | Trial completion date: Oct 2024 ➔ Feb 2023 | Recruiting ➔ Withdrawn | Trial primary completion date: May 2023 ➔ Feb 2023

Trial completion date • Trial primary completion date • Trial withdrawal • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

GC wins regulatory nod for trials of psoriasis therapy (Korea Biomedical Review) - "GC Lab Cell said...that it has won the Ministry of Food and Drug Safety’s approval for phase 1 clinical trial of CT303, a candidate substance of stem cell therapy for psoriasis...The trial is designed to analyze the safety, and drug tolerance of repetitive single dose administers of CT303 (human tonsil-derived mesenchymal stem cell) on 24 moderate-to-severe plaque psoriasis (PsO) patients...The institutions include Seoul National University Hospital, Pusan National University Hospital, CHA University, and CHA Bundang Medical Center."

New P1 trial • Psoriasis